Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of moderate to severe plaque psoriasis receiving etanercept treatment for a minimum duration of 1 year.~* Age ≥18 years old.~* No history of using a biological treatment, other than etanercept, for treatment of moderate to severe plaque psoriasis or any other reason.~Exclusion Criteria:~* Etanercept use for treatment moderate to severe plaque psoriasis less than 1 year duration.~* Previous use of other biological treatments for any reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with moderate to severe plaque psoriasis (Type: None): Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).